W hen studied in clinical trials, the current standardofcare therapy for patients with hepatitis C virus (HCV) genotype 2 or 3 infection -pegylated interferon in combination with ribavirin for 24 weeksresulted in a sustained virologic response in 70 to 85% of patients who had not received prior treatment and in 55 to 60% of those who had received treatment. [1] [2] [3] [4] However, a substantial pro portion of patients with HCV infection remain untreated owing to absolute or relative contra indications to interferon therapy, such as hepatic decompensation, autoimmune disease, and psy chiatric illness. 5 In addition, interferon causes a range of constitutional symptoms or hematologic abnormalities that may require discontinuation of therapy in a considerable number of patients. 6 Some patients decide against interferon therapy for a variety of reasons, including aversion to in jections and anxiety about the adverse events as sociated with treatment. Moreover, the 15 to 30% of patients with HCV genotype 2 or 3 infection who do not have a response to interferon therapy have no alternate therapeutic options. These populations -which by one estimate constitute the majority of patients infected with HCV 5 -are in need of effective treatments.
Sofosbuvir is an oral nucleotide analogue in hibitor of the HCVspecific NS5B polymerase with in vitro activity against all HCV genotypes. 7 In a phase 2 study of treatment for 12 weeks with sofosbuvir and ribavirin in patients with HCV genotype 2 or 3 infection, 10 of 10 previously untreated patients (100%) and 17 of 25 previously treated patients (68%) had a sustained virologic response. 8, 9 This oral regimen had an acceptable safety profile, with no premature discontinua tions of sofosbuvir therapy owing to adverse events. 9 In this article, we present the results of two phase 3 trials of treatment with sofosbuvir and ribavirin in patients with HCV genotype 2 or 3 infection for whom treatment with peginterfer on was not an option and in those who did not have a response to prior interferon treatment. The primary objective of both studies was to evaluate the efficacy of sofosbuvir and ribavirin, as mea sured by the proportion of patients with a sus tained virologic response at 12 weeks after the end of treatment, and to evaluate the safety of this regimen.
ME THODS

STUDY DESIGNS AND PATIENTS
We conducted two multicenter, randomized trials to assess the efficacy and safety of sofosbuvir administered with ribavirin in patients chroni cally infected with HCV genotype 2 or 3. In both studies, patients received sofosbuvir (Gilead Sci ences) and ribavirin (Ribasphere, Kadmon) or matching placebo. Sofosbuvir was administered orally at a dose of 400 mg once daily. Ribavirin was administered orally twice daily, with doses determined according to body weight (1000 mg daily in patients with a body weight of <75 kg, and 1200 mg daily in patients with a body weight of ≥75 kg).
The POSITRON trial was a blinded, placebo controlled study that compared 12 weeks of treat ment with sofosbuvir and ribavirin with match ing placebo in patients who had previously discontinued interferon therapy owing to unac ceptable adverse events, who had a concurrent medical condition precluding therapy with an interferoncontaining regimen, or who had de cided against treatment with an interferoncon taining regimen (see the Supplementary Appen dix, available with the full text of this article at NEJM.org, for further details). Prior treatment failure with an interferonbased regimen was not a reason for exclusion. Approximately 20% of patients enrolled could have evidence of com pensated cirrhosis at screening.
Patients were enrolled at 63 sites in the United States, Canada, Australia, and New Zealand from March 2012 through May 2012. Randomization was performed centrally in a 3:1 ratio with stratification according to the presence or ab sence of cirrhosis.
The FUSION study was a blinded, activecon trol study involving patients who had not had a response to prior treatment with an interferon containing regimen. Approximately 30% of the patients enrolled could have evidence of com pensated cirrhosis at screening.
Patients were enrolled at 67 sites in the United States, Canada, and New Zealand from May 2012 through July 2012. Patients were randomly assigned in a 1:1 ratio to one of two treatment groups: 12 weeks of sofosbuvir and ribavirin, followed by 4 weeks of matching placebo, or 16 weeks of sofosbuvir and ribavirin. Random 3 ization was stratified according to the presence or absence of cirrhosis and HCV genotype 2 or 3 infection. Full eligibility criteria for both trials, including details of the assessment of cirrhosis, are provided in the Supplementary Appendix.
STUDY ASSESSMENTS
Screening assessments included measurement of the serum HCV RNA level and IL28B genotyping in addition to standard laboratory and clinical tests. The HCV RNA level was measured with the COBAS TaqMan HCV Test, version 2.0, for use with the High Pure System (Roche Molecular Systems), with a lower limit of quantification of 25 IU per milliliter. HCV genotype and subtype were determined with the use of the Siemens Ver sant HCV Genotype 2.0 Assay. Status with respect to the gene encoding interleukin 28B [IL28B], an indicator of the response to HCV therapy, was determined by means of polymerasechain reaction amplification and sequencing of the rs12979860 singlenucleotide polymorphism. 10 Assessments during treatment included stan dard laboratory testing, measurement of serum HCV RNA level, assessment of vital signs, and symptomdirected physical examinations. All ad verse events were recorded and graded according to a standardized scale.
Patients with virologic failure (see the Supple mentary Appendix for the definition) underwent resistance testing. We conducted analyses of nu cleotide changes in the HCV NS5B gene (which can confer resistance to therapy) in samples col lected at baseline and at the time of virologic failure. DDL Diagnostics Laboratory (Rijswijk, the Netherlands) performed NS5B amplification and population sequencing, and WuXi Apptec (Shang hai, China) performed deepsequencing assays to characterize virologic resistance.
STUDY OVERSIGHT
Both studies were approved by the institutional review board or independent ethics committee at each participating site and were conducted in compliance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local reg ulatory requirements. They were designed and conducted according to their respective protocols by the sponsor (Gilead Sciences) in collaboration with the principal investigators. The sponsor col lected the data, monitored study conduct, and performed the statistical analyses. An indepen dent data and safety monitoring committee re viewed the progress of both studies. The inves tigators, participating institutions, and sponsor agreed to maintain confidentiality of the data.
All the authors had access to the data, assume responsibility for the integrity and completeness of the reported data, and vouch for the fidelity of this report to the study protocols, available at NEJM.org. The manuscript was prepared by the sponsor and a professional writer, who is an employee of the sponsor, with input from all the authors. The decision to submit the manu script for publication was made by all the au thors.
STATISTICAL ANALYSIS
For the POSITRON study, we calculated that a sample of 180 patients in the sofosbuvir group and 60 in the placebo group would provide 99% power to detect a betweengroup difference in the rate of a sustained virologic response of 40% with the use of a twosided continuitycorrected chisquare test at a significance level of 0.05. For the FUSION study, we calculated that a sample of 100 patients in each group would provide more than 97% power to detect an improvement of at least 20% in the rate of a sustained virologic re sponse, as compared with a historical control rate of 25%, and would provide 82% power to detect a difference of 20% in response rates be tween the 12week and 16week treatment groups (see the Supplementary Appendix for a fuller ex planation of the calculation of the historical con trol rate).
In a secondary analysis that was performed with the use of a Cochran-Mantel-Haenszel test according to the stratification factors at random ization, we compared differences in the rates of a sustained virologic response at 12 and 16 weeks of treatment in the FUSION study. The modified intentiontotreat analyses included data from all patients who underwent randomization and re ceived at least one dose of study medication. Multivariable logisticregression analyses involv ing baseline demographic and clinical character istics were performed, and a stepwise procedure was used to identify independent predictors of a sustained virologic response (Tables S5, S6 , and S9 through S12 in the Supplementary Ap pendix). 
R E SULT S
BASELINE CHARACTERISTICS
A total of 410 patients with HCV genotype 2 or 3 infection for whom interferon treatment was not an option were initially screened for the POSITRON trial. Of these patients, 280 underwent random ization, and 278 began treatment (Fig. S1 in the Supplementary Appendix). A total of 277 patients who had received prior treatment for HCV geno type 2 or 3 infection were initially screened for the FUSION study; 202 underwent randomization, and 201 began treatment ( Fig. S2 in the Supple mentary Appendix). The demographic and base line clinical characteristics were balanced be tween the two groups in each study.
In the POSITRON trial, the distribution of pa tients on the basis of the classification that inter feron therapy was not an option (contraindica tion, unacceptable side effects, or patient's decision) was similar between the treatment and placebo groups ( Table 1) . The most common reasons that interferon treatment was not an option were clinically significant psychiatric disorders (in 57% of patients) and autoimmune disorders (in 19%) (Fig. S3 in the Supplementary Appendix). Approximately 75% of the previously treated patients enrolled in the FUSION trial had either virologic breakthrough during the prior treat ment or virologic relapse afterward; the remain der did not have a response. A total of 16% of the patients in the POSITRON study and 34% of those in the FUSION study had cirrhosis. A higher percentage of patients with HCV geno type 3 infection were enrolled in the FUSION study (63% of patients) than in the POSITRON study (49%).
EFFICACY
Overall Population
Treatment with sofosbuvir and ribavirin resulted in a rapid decline in circulating HCV RNA levels, with similar reductions in the two studies and among patients with HCV genotype 2 or 3 infec tion. By week 2 of treatment, 81 to 91% of pa tients in the sofosbuvir groups had an HCV RNA level that was less than the lower limit of quanti fication. By week 4, the rates of virologic sup pression were 97 to 99%, and at the end of treat ment, no patient who could be evaluated had an HCV RNA level that was higher than the lower limit of quantification (Table 2) . Among the 402 patients receiving sofosbuvir in these studies, none had virologic breakthrough during treat ment, and thus all treatment failures involved virologic relapse after the cessation of therapy.
POSITRON Trial
In the population of patients for whom interfer on treatment was not an option, the rate of sus tained virologic response at 12 weeks after treat ment was 78% (95% confidence interval [CI], 72 to 83) among patients receiving sofosbuvir and ribavirin, as compared with 0% among those re ceiving placebo (P<0.001) ( Table 2 ). There was complete concordance (100%) between rates of sustained virologic response at 12 weeks and at 24 weeks among patients who received sofosbu vir and ribavirin, with none of the 153 patients who could be evaluated having virologic relapse after week 12.
Rates of sustained virologic response in pa tient subgroups are shown in Figure 1 and in Tables S3 and S4 in the Supplementary Appendix. * No significant differences were found between the groups in either study. ALT denotes alanine aminotransferase, HCV hepatitis C virus, and ULN upper limit of the normal range. † The body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ Race and ethnic group were self reported. One patient declined to report ethnic group. § These patients, who were found to have genotype 1 infection by deep sequencing after randomization, were excluded from the efficacy analysis but not from the safety analyses. ¶ Common contraindications for interferon treatment included psychiatric disorders (in 57% of patients) and autoimmune disorders (in 19%). Logisticregression analysis showed that HCV genotype 3 infection was significantly associat ed with reduced rates of sustained virologic re sponse, as compared with HCV genotype 2 infec tion (Table S6 in the Supplementary Appendix).
Among patients who received sofosbuvir and ribavirin, 93% of patients with HCV genotype 2 infection had a sustained virologic response, as compared with 61% of those with HCV genotype 3 infection. Likewise, 81% of patients without cir rhosis (92% of patients with HCV genotype 2 infection and 68% of those with HCV genotype 3 infection) had a sustained virologic response, as compared with 61% of patients with cirrhosis (94% of patients with HCV genotype 2 infection and 21% of those with HCV genotype 3 infection).
FUSION Trial
The rates of sustained virologic response achieved with sofosbuvir and ribavirin in the population of patients with prior treatment were superior to the historical control rate of 25%, with rates of 50% (95% CI, 40 to 60) in the 12week group and 73% (95% CI, 63 to 81) in the 16week group (P<0.001 for each comparison). The secondary analysis comparing rates of sustained virologic response between the groups showed that patients receiving 16 weeks of treatment had a signifi cantly higher rate of sustained virologic response than patients receiving 12 weeks of treatment (difference, −23 percentage points; 95% CI, −35 to −11; P<0.001) (Fig. 1) .
The rates of sustained virologic response in various patient subgroups are shown in Figure 1 and in Tables S7 and S8 in the Supplementary Appendix. Multivariate logisticregression model ing was performed independently for each treat ment group to investigate predefined covariate effects. HCV genotype 3 infection, as compared with genotype 2 infection, was significantly as sociated with a lower response rate with both 12 and 16 weeks of treatment (Tables S10 and S12 in the Supplementary Appendix). The rates of sus tained virologic response among patients with HCV genotype 2 infection who received 12 weeks of treatment and those who received 16 weeks of treatment were 86% and 94%, respectively (dif ference, −8 percentage points; 95% CI, −24 to 9), as compared with 30% and 62% for 12 and 16 weeks of treatment, respectively, among patients with HCV genotype 3 infection (difference, −32 percentage points; 95% CI, −48 to −15). Virologic breakthrough during treatment -no. The position of each symbol indicates the rate of sustained virologic response 12 weeks after the end of treatment for each prespecified subgroup; the horizontal lines indicate 95% confidence intervals. The vertical dashed lines represent the overall rates of sustained virologic response for the sofosbuvir treatment groups. Arrows indicate confidence intervals that exceed the x-axis scale. Race and ethnic group were self-reported. The body-mass index is the weight in kilograms divided by the square of the height in meters. The P values shown are for the interactions between treatment durations and subgroups in the FUSION study. There were not enough black patients in the study for the calculation of an interaction P value. For confidence intervals of response rates, see Tables S3 and S7 in Cirrhosis was associated with a decreased rate of sustained virologic response, particularly among patients with HCV genotype 3 infection who received 12 weeks of treatment. Among patients with cirrhosis who received 12 weeks of treat ment, the rate of response was 31% (60% with HCV genotype 2 infection and 19% with HCV genotype 3 infection), as compared with 61% among patients without cirrhosis (96% with HCV genotype 2 infection and 37% with HCV geno type 3 infection). Among patients with cirrhosis who received 16 weeks of treatment, the rate of response was 66% (78% with HCV genotype 2 infection and 61% with HCV genotype 3 infection) as compared with 76% among patients without cirrhosis (100% with HCV genotype 2 infection and 63% with HCV genotype 3 infection).
VIROLOGIC RESISTANCE TESTING
No patient receiving sofosbuvir in either study had virologic breakthrough during treatment or failed to have a response to treatment. Among the 42 patients in the POSITRON study and the 73 patients in the FUSION study who had a re lapse after the end of treatment, sequencing analysis of samples collected at time of relapse showed no resistanceassociated variants (see the Supplementary Appendix).
SAFETY
Premature discontinuation of the study drug due to adverse events was uncommon in all groups: in the FUSION study, one patient in the 12week group discontinued treatment during the 4week placebo phase of dosing; in the POSITRON study, four patients who received sofosbuvir and riba virin (2%) discontinued treatment, as compared with three who received placebo (4%). The rates of serious adverse events in the POSITRON trial were 5% in the group that received sofosbuvir and ribavirin and 3% in the placebo group; in the FUSION study, the rates were 5% in the 12week group and 3% in the 16week group (Table 3, and  Tables S17 and S18 in the Supplementary Ap pendix).
In the POSITRON study, the differences in adverse events between the placebo and active treatment groups included higher rates of fa tigue and insomnia among patients receiving sofosbuvir and ribavirin (Table 3, and Table S15 in the Supplementary Appendix). As expected, the incidence of anemia was higher among patients receiving sofosbuvir and ribavirin than among patients receiving placebo (Fig. S7 and S9 in the Supplementary Appendix). 11 Otherwise, the rates of laboratory abnormalities, including white cell, neutrophil, and platelet counts, did not differ significantly between the two groups.
The incidences of adverse events and labora tory abnormalities among patients with cirrhosis who received sofosbuvir and ribavirin were sim ilar to those among patients without cirrhosis (Table S19 in the Supplementary Appendix). In addition, the overall safety profile in patients receiving 16 weeks of therapy was similar to that observed in patients receiving 12 weeks of ther apy (Table 3) .
DISCUSSION
In these phase 3 studies, 12 or 16 weeks of treat ment with sofosbuvir and ribavirin resulted in a sustained virologic response in 78% of patients for whom interferon treatment was not an option and in 50 to 73% of patients with prior treatment failure. High response rates were observed among patients with HCV genotype 2 infection in all pa tient subgroups in both studies. Response rates among patients with HCV genotype 3 infection were lower than the rates among those with HCV genotype 2 infection, especially in the subgroup of patients with cirrhosis.
Extending the duration of treatment from 12 to 16 weeks in patients with prior treatment failure significantly increased the rates of sus tained virologic response among patients with HCV genotype 3 infection and among patients with cirrhosis by decreasing the rate of relapse. Relapse accounted for all treatment failures in both studies. No virologic resistance was detected in patients who did not have a sustained viro logic response.
An explanation for the lower rates of sus tained virologic response among patients with HCV genotype 3 infection, as compared with those who had HCV genotype 2 infection -a difference that has also been observed among patients treated with peginterferon and ribavi rin 12 -remains unclear. Although virologic declines during treatment are similar with the two genotypes, the lower rates of relapse among patients with HCV genotype 2 infection indicate that virologic clearance is likely to be slower in some patients with HCV genotype 3 infection. Thus, a longer period of virologic suppression may be required to eliminate residual viral reservoirs in patients with HCV genotype 3 infection. This is supported by the observation that prolonging the treatment duration by as short a period as 4 weeks significantly improved the rates of sus tained virologic response among the patients with HCV genotype 3 infection in whom prior treatment had failed, especially among those with factors associated with a poor response, such as cirrhosis. Studies exploring 24 weeks of treatment with sofosbuvir plus ribavirin in pa (8) 11 ( tients with HCV genotype 3 infection will help determine whether response rates can be in creased by extending the duration of treatment. An alternative hypothesis is that patients with HCV genotype 3 infection may require addi tional immune modulation or more potent anti viral suppression to enhance virologic clearance with a shorter, 12week duration of treatment. Thus, another possible approach to improving the response in patients with HCV genotype 3 infection is the addition of other directacting antiviral agents or peginterferon to the regimen. A study evaluating such a regimen, also now re ported in the Journal, showed high rates of sus tained virologic response among patients with HCV genotype 1, 4, 5, or 6 infection. 13 On the basis of these findings, a combined regimen warrants exploration in future clinical trials in volving patients with HCV genotype 3 infection.
In both of our studies, the rate of premature discontinuation of treatment with sofosbuvir and ribavirin due to adverse events was low (1 to 2%) and was similar to the rate among patients re ceiving placebo in the POSITRON trial (4%). Whereas adverse events associated with ribavirin therapy -fatigue, insomnia, and anemiawere higher in the groups that received sofosbu vir plus ribavirin, other common adverse events occurred at similar rates in the treatment and placebo groups. 3, 14 There were no notable differ ences in adverse events during treatment with sofosbuvir and ribavirin among patients receiv ing 16 weeks of treatment or among those with cirrhosis.
There are currently no effective treatment op tions for patients with HCV genotype 2 or 3 in fection who do not have a sustained virologic response with the current standard of care of 24 weeks of treatment with peginterferon and riba virin and for those who have medical contraindi cations to interferon therapy or decide against it. Our findings suggest that 12 weeks of treatment with sofosbuvir and ribavirin can be an effective option for patients with HCV genotype 2 infec tion. However, for patients with genotype 3 in fection, particularly those who have cirrhosis or who have not had a response to prior treatment with interferon, extending the duration of treat ment to 16 weeks may provide an additional benefit.
